BDBM372439 3,5-diamino-N-(N-(4-(6-((S)-4-amino-3-(3-(bis((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)propylamino)-4-oxobutyl)naphthalen-2-yl)butyl)carbamimidoyl)-6-chloropyrazine-2-carboxamide::US10246425, Compound XIII-bb

SMILES NC(=O)[C@H](CCc1ccc2cc(CCCCNC(=N)NC(=O)c3nc(Cl)c(N)nc3N)ccc2c1)NCCCN(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI Key InChIKey=UXMVMPRLBCKSGM-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 372439   

TargetSodium channel protein type 5 subunit alpha(Human)
Parion Sciences

US Patent
LigandPNGBDBM372439(US10246425, Compound XIII-bb | 3,5-diamino-N-(N-(4...)
Affinity DataIC50: 12.5nMAssay Description:One assay used to assess mechanism of action and/or potency of the compounds of the present invention involves the determination of lumenal drug inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent